Center-Authored Papers

Filters: Author is Coleman, Ilsa  [Clear All Filters]
2008
Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, Nelson PS, Vasioukhin VI.  2008.  A causal role for ERG in neoplastic transformation of prostate epithelium.. Proceedings of the National Academy of Sciences of the United States of America. 105(6):2105-10. Abstract
2009
Sprenger CCT, Haugk K, Sun S, Coleman I, Nelson PS, Vessella RL, Ludwig DL, Wu JD, Plymate SR.  2009.  Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(24):7634-7641. Abstract
Pritchard C, Mecham B, Dumpit R, Coleman I, Bhattacharjee M, Chen Q, Sikes RA, Nelson PS.  2009.  Conserved gene expression programs integrate mammalian prostate development and tumorigenesis.. Cancer research. 69(5):1739-47. Abstract
Koreckij TD, Trauger RJ, Montgomery RB, Pitts TEM, Coleman I, Nguyen H, Reading CL, Nelson PS, Vessella RL, Corey E.  2009.  HE3235 inhibits growth of castration-resistant prostate cancer.. Neoplasia (New York, N.Y.). 11(11):1216-25. Abstract
2010
Sharma A, Yeow W-S, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CES, Witkiewicz AK et al..  2010.  The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.. The Journal of clinical investigation. 120(12):4478-92. Abstract
Risk MC, Knudsen BS, Coleman I, Dumpit RF, Kristal AR, Lemeur N, Gentleman RC, True LD, Nelson PS, Lin DW.  2010.  Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(22):5414-23. Abstract
2011
Schoenherr RM, Kelly-Spratt KS, Lin C, Whiteaker JR, Liu T, Holzman T, Coleman I, Feng L-C, Lorentzen TD, Krasnoselsky AL et al..  2011.  Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer.. Proteomics. Clinical applications. 5(3-4):179-88. Abstract
Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ et al..  2011.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.. Proceedings of the National Academy of Sciences of the United States of America. 108(41):17087-92. Abstract
Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu SX, Brown M et al..  2011.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.. Cancer cell. 20(4):457-71. Abstract
2012
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS.  2012.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B.. Nature medicine. Abstract
Goel HL, Chang C, Pursell B, Leav I, Lyle S, Xi HS, Hsieh C-C, Adisetiyo H, Roy-Burman P, Coleman I et al..  2012.  VEGF/Neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-1R define a novel mechanism of aggressive prostate cancer.. Cancer discovery. Abstract
2013
Gao L, Schwartzman J, Gibbs A, Lisac R, Kleinschmidt R, Wilmot B, Bottomly D, Coleman I, Nelson P, McWeeney S et al..  2013.  Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation.. PloS one. 8(5):e63563. Abstract
Welty CJ, Coleman I, Coleman R, Lakely B, Xia J, Chen S, Gulati R, Larson SR, Lange PH, Montgomery B et al..  2013.  Single cell transcriptomic analysis of prostate cancer cells.. BMC molecular biology. 14:6. Abstract
Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R et al..  2013.  A Three-Marker FISH Panel Detects More Genetic Aberrations of AR, PTEN and TMPRSS2/ERG in Castration-Resistant or Metastatic Prostate Cancers than in Primary Prostate Tumors.. PloS one. 8(9):e74671. Abstract
Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B et al..  2013.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.. The Prostate. 73(9):932-40. Abstract
Bluemn EG, Spencer SE, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C et al..  2013.  PPP2R2C loss promotes castration-resistant prostate cancer growth and is associated with increased prostate cancer-specific mortality.. Molecular cancer research : MCR. 11(6):568-578. Abstract
Liu G, Sprenger C, Sun S, Epilepsia KS, Haugk K, Zhang X, Coleman I, Nelson PS, Plymate S.  2013.  AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.. Neoplasia (New York, N.Y.). 15(9):1009-17. Abstract
2014
Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.  2014.  Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.. Cancer letters. Abstract
2015
Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E et al..  2015.  Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.. PloS one. 10(6):e0130565. Abstract
Haider M, Zhang X, Coleman I, Ericson N, True LD, Lam H-M, Brown LG, Ketchanji M, Nghiem B, Lakely B et al..  2015.  Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.. Clinical & experimental metastasis. Abstract
Huber RM, Lucas JM, Gomez-Sarosi LA, Coleman I, Zhao S, Coleman R, Nelson PS.  2015.  DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.. Oncotarget. 6(4):2134-47. Abstract
Zhang X, Coleman I, Brown LG, True LD, Kollath L, Lucas JM, Lam H-M, Dumpit R, Corey E, Chéry L et al..  2015.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Nguyen LT, Tretiakova MS, Silvis MR, Lucas J, Klezovitch O, Coleman I, Bolouri H, Kutyavin VI, Morrissey C, True LD et al..  2015.  ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors.. Cancer cell. 27(6):797-808. Abstract
Rubicz R, Zhao S, April C, Wright JL, Kolb S, Coleman I, Lin DW, Nelson PS, Ostrander EA, Feng Z et al..  2015.  Expression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohort.. The Prostate. Abstract
2016
Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I et al..  2016.  Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.. Clinical & experimental metastasis. 33(4):325-37. Abstract